Acumen Pharmaceuticals, Inc. (ABOS) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and welcome to the Acumen Pharmaceuticals second quarter 2025 conference call and webcast. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question at that time, please press star 1-1. As a reminder, this call may be recorded. I would like to turn the call over to Alex Braun, Head of Investor Relations. Please go ahead. Thanks, Michelle. Good morning, and welcome to the Acumen conference call to discuss our business update and financial results for the quarter ended June 30th, 2025. With me today are Dan O'Connell, our Chief Executive Officer, Dr. Jim Doherty, our Chief Development Officer, and Matt Buga, our CFO and Chief Business Officer. Dan and Matt have some prepared remarks, and then we'll open the call for questions. Joining for the Q&A session, we also have Dr. Eric Siemers, our Chief Medical Officer. Before we begin, we encourage listeners to go to the Investors section of the Acumen website to find our press release issued this morning that we'll discuss today. Please note that during today's conference call, we may make forward-looking statements within the meaning of the federal securities laws, including statements concerning our financial outlook and expected business plans. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Please see slide two of our corporate presentation, our press release issued this morning, and our most recent annual and quarterly reports filed with the SEC for important risk factors that could cause our actual results to differ materially from those expressed or implied in the forward-looking statements. We undert...